unknown
Stage
1
Investors
About
LoQus23 develops small molecule inhibitors targeting somatic expansion in DNA to treat Huntington’s Disease and other triplet repeat expansion neurodegenerative diseases by slowing DNA instability and neurodegeneration.
Explore LoQus23's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.